Lepercq De Neuflize Asset Management’s LAVA Therapeutics LVTX Stock Holding History

Lepercq De Neuflize Asset Management’s Portfolio LVTX Stock Details LVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-31,000	Closed	-$48.4K	–	18
2025 Q3	$48.4K	Hold	31,000	–	–	0.03%	9
2025 Q2	$40.9K	Buy	31,000 +8,000	+35%	+$10.2K	0.03%	10
2025 Q1	$29.2K	Buy	+23,000	New	+$25.6K	0.03%	11

Lepercq De Neuflize Asset Management's LVTX Position: Q4 2025 in Review

Lepercq De Neuflize Asset Management sold out of LAVA Therapeutics (LVTX) in Q4 2025, closing a stake of 31,000 shares — an estimated $48.4K sold.

Lepercq De Neuflize Asset Management first reported a position in LVTX in Q1 2025 and held it in 3 quarters. The position peaked at $48.4K in Q3 2025. 0 funds tracked by Wall St. Rank hold LVTX as of Q4 2025.

Lepercq De Neuflize Asset Management reported no remaining LAVA Therapeutics position as of Q4 2025 after selling out during the quarter.
Lepercq De Neuflize Asset Management sold 31,000 LAVA Therapeutics shares in Q4 2025, an estimated $48.4K.
Lepercq De Neuflize Asset Management first reported a position in LAVA Therapeutics in Q1 2025 and held it in 3 quarters.
Lepercq De Neuflize Asset Management's LAVA Therapeutics position peaked at $48.4K in Q3 2025.
0 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q4 2025.

Based on Lepercq De Neuflize Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.